WHO ICTRP trial
Study on intensive chemotherapy in patients with breast cancer with 1 to 3…
EUCTR2011-001237-16-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2011-001237-16-NL |
|---|---|
| Public title | Study on intensive chemotherapy in patients with breast cancer with 1 to 3 metastatic lesions. The breast tumor has to be hormonal receptor negative and HER2 negative. |
| Scientific title | High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency - OLIGO study |
| Primary sponsor | NKI-AVL |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Netherlands |
| Conditions | Oligo metastatic triple negative or BRCA1/1 like breast cancer MedDRA version: 13.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts… |
| Interventions | Trade Name: Docetaxel Hospira Product Name: Docetaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DOCETAXEL CAS Number: 114977-28-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type… |
| Registration date | Nov 5, 2011 |
| Secondary IDs | N11OLG |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: